WinzWorld的个人主页 - 老虎社区

WinzWorld

WinzWorld

暂无个人介绍

IP属地：未知

4关注

0粉丝

0主题

0勋章

2021-12-29

Thanks for sharing! 👍🏻

APPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>APPS 股票提醒：有关 Google 交易的 7 件事，您需要了解今天提振 Digital Turbine 股价</blockquote>

2021-12-24

Merry Christmas 🥂

抱歉，原内容已删除

2021-12-24

Watching this space closely 😬

How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服 COVID-19 药丸能带来多少收入？</blockquote>

2021-12-24

The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔

Nio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行提出了有吸引力的购买机会，蔚来受到关注</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4097106422038760","uuid":"4097106422038760","gmtCreate":1634023048628,"gmtModify":1640141424618,"name":"WinzWorld","pinyin":"winzworld","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":"80.23%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":696418210,"gmtCreate":1640745892996,"gmtModify":1640745892996,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097106422038760","authorIdStr":"4097106422038760"},"themes":[],"title":"","htmlText":"Thanks for sharing! 👍🏻","listText":"Thanks for sharing! 👍🏻","text":"Thanks for sharing! 👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696418210","repostId":"1143687105","repostType":4,"repost":{"id":"1143687105","kind":"news","pubTimestamp":1640743835,"share":"https://www.laohunote.com/m/news/1143687105?lang=zh_CN&edition=full","pubTime":"2021-12-29 10:10","market":"us","language":"en","title":"APPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>APPS 股票提醒：有关 Google 交易的 7 件事，您需要了解今天提振 Digital Turbine 股价</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143687105","media":"InvestorPlace","summary":"Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed ","content":"<p><div> Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google...</p><p><blockquote><div>Digital Turbine（纳斯达克股票代码：APPS）的股价今天下滑，尽管这家科技公司宣布已同意与Alphabet（纳斯达克股票代码：GOOG，纳斯达克股票代码：GOOGL）的谷歌公司建立 “多年战略合作伙伴关系”。</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>APPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>APPS 股票提醒：有关 Google 交易的 7 件事，您需要了解今天提振 Digital Turbine 股价</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAPPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>APPS 股票提醒：有关 Google 交易的 7 件事，您需要了解今天提振 Digital Turbine 股价</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-29 10:10</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google...</p><p><blockquote><div>Digital Turbine（纳斯达克股票代码：APPS）的股价今天下滑，尽管这家科技公司宣布已同意与Alphabet（纳斯达克股票代码：GOOG，纳斯达克股票代码：GOOGL）的谷歌公司建立 “多年战略合作伙伴关系”。</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOOG":"谷歌","APPS":"Digital Turbine Inc."},"source_url":"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143687105","content_text":"Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google. Digital Turbine’s technology enhances mobile ads and the monetization of mobile traffic. In early trading, APPS stock is down 1.73% to $62.34 amid much higher than normal volume.\nDigital Turbine did not disclose the financial terms of the alliance. However, here are seven things that we do know about the deal.\n\nDigital Turbine is going to collaborate with Google Cloud’s partner,SADA.\nDigital Turbine and SADA will attempt to quickly improve and geographically expand Google Cloud’s “enterprise and cloud solutions.”\nThe two companies will also seek to develop additional “growth and monetization” opportunities for Google’s “partners.”\nDigital Turbine will use Google’s “advanced cloud and enterprise infrastructure.”\nThe company will, for the first time, enhance the “mobile experiences” of overseas Android users.\nMore specifically, Digital Turbine will enable “app discovery for nearly a billion Android devices globally.”\nDigital Turbine will be supporting “mobile, TV and connected devices” that utilize Android.\n\nOther Things to Know About APPS Stock\nIn the last month, APPS stock has rallied over 20%. However, shares are still down nearly 30% from their late October peak. The stock now has a market capitalization of nearly $6.4 billion and is trading at a hefty, but not huge, trailing price-to-sales ratio of 7.45.\nAdditionally, institutional investors hold 75% of the shares. Among the largest institutional owners of the stock, as of Sept. 29, were Blackrock(NYSE:BLK) with a 10% stake,Wellington Management Group with a 6.55% stake,Vanguard Group with a 9.17% stake,State Street(NYSE:STT) with a 2.86% stake, and JPMorgan(NYSE:JPM), which owned 1.86% of the company.","news_type":1,"symbols_score_info":{"GOOG":0.9,"APPS":0.9}},"isVote":1,"tweetType":1,"viewCount":3591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698332753,"gmtCreate":1640303160546,"gmtModify":1640303160546,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097106422038760","authorIdStr":"4097106422038760"},"themes":[],"title":"","htmlText":"Merry Christmas 🥂","listText":"Merry Christmas 🥂","text":"Merry Christmas 🥂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698332753","repostId":"2193078140","repostType":2,"isVote":1,"tweetType":1,"viewCount":3242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698333856,"gmtCreate":1640302633989,"gmtModify":1640302633989,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097106422038760","authorIdStr":"4097106422038760"},"themes":[],"title":"","htmlText":"Watching this space closely 😬","listText":"Watching this space closely 😬","text":"Watching this space closely 😬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698333856","repostId":"1172289344","repostType":4,"repost":{"id":"1172289344","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohunote.com/m/news/1172289344?lang=zh_CN&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服 COVID-19 药丸能带来多少收入？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga Earnings","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p><p><blockquote><b>辉瑞公司。</b>周三宣布其口服 COVID-19 抗病毒药物，<b>帕克斯洛维德，</b>已被美国授权使用。食品药品监督管理局。</blockquote></p><p> <b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p><p><blockquote><b>辉瑞分析师：</b>SVB Leerink 分析师 Geoffrey Porges 对辉瑞给予市场表现评级，目标价为 52 美元。</blockquote></p><p> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p><p><blockquote>美国银行证券分析师杰夫·米查姆维持中性评级，目标价为 59 美元。</blockquote></p><p> <b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p><p><blockquote><b>广泛的标签，增加供应，使辉瑞占据市场主导地位：</b>辉瑞提前获得口服 COVID-19 治疗的批准<b>默克公司。</b>波吉斯在一份报告中表示，该公司比辉瑞早一个多月提交了莫努匹拉韦的申请。</blockquote></p><p> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p><p><blockquote>该分析师认为辉瑞明年 Paxlovid 的预期供应量将增加到 1.2 亿个疗程，意义重大。分析师表示，该公司将销售和分销其中大部分课程，其收入远远超过 SVB Leerink 目前预测的 2022 年 Paxlovid 销售额为 240 亿美元，2023 年为 330 亿美元。</blockquote></p><p> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p><p><blockquote>分析师表示，2024 年收入贡献将降至 100 亿美元。他补充说，预计 2022-24 年 Paxlovid 的总销售额为 670 亿美元，远高于共识。</blockquote></p><p> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p><p><blockquote>Porges说，药物相互作用对Paxlovid摄取的影响将是适度的，因为清单上的许多药物可以在Paxlovid治疗的短时间内暂停，而不会对患者产生重大影响。他补充说，可能被排除在使用 Paxlovid 之外的患者是那些患有严重肝脏或肾脏损害的患者以及那些患有不受控制的 HIV-1 感染的患者。</blockquote></p><p> The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p><p><blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并描绘了与默克公司的molnupiravir相比相对良性的风险/效益概况，后者在动物中显示出胚胎发育和胎儿生长风险。</blockquote></p><p> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p><p><blockquote>Paxlovid 比一些领先的抗体疗法具有更好的疗效，而且由于一些抗体疗法对奥密克戎变异株失去了疗效，Paxlovid 将成为“对医生和患者极具吸引力的选择”，Porges 说。</blockquote></p><p> <b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p><p><blockquote><b>美国银行表示，Paxlovid 应该仍然是一个稳定的贡献者：</b>美国银行分析师米查姆表示，2022 年销售辉瑞生产的每个疗程的 Paxlovid 应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在 2022 年确认每剂疫苗的收入。</blockquote></p><p> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p><p><blockquote>分析师表示，从长远来看，Paxlovid 可能会保持稳定的贡献者。</blockquote></p><p> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p><p><blockquote>“我们预计突破性感染将在地方病阶段继续定期发生，虽然疫苗和既往感染的基线免疫水平将限制严重程度，但我们预计高危个体中发生的新冠病例的治疗将是标准护理，”米查姆说。</blockquote></p><p> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p><p><blockquote>这位分析师表示，预计政府机构将储备默克的药丸，因此可能会进行初步销售。他补充说，从长远来看，Paxlovid 可能是首选药物。</blockquote></p><p> <b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p><p><blockquote><b>辉瑞价格走势：</b>辉瑞股价周四收盘下跌 1.41%，至 58.71 美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服 COVID-19 药丸能带来多少收入？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服 COVID-19 药丸能带来多少收入？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-12-24 07:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p><p><blockquote><b>辉瑞公司。</b>周三宣布其口服 COVID-19 抗病毒药物，<b>帕克斯洛维德，</b>已被美国授权使用。食品药品监督管理局。</blockquote></p><p> <b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p><p><blockquote><b>辉瑞分析师：</b>SVB Leerink 分析师 Geoffrey Porges 对辉瑞给予市场表现评级，目标价为 52 美元。</blockquote></p><p> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p><p><blockquote>美国银行证券分析师杰夫·米查姆维持中性评级，目标价为 59 美元。</blockquote></p><p> <b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p><p><blockquote><b>广泛的标签，增加供应，使辉瑞占据市场主导地位：</b>辉瑞提前获得口服 COVID-19 治疗的批准<b>默克公司。</b>波吉斯在一份报告中表示，该公司比辉瑞早一个多月提交了莫努匹拉韦的申请。</blockquote></p><p> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p><p><blockquote>该分析师认为辉瑞明年 Paxlovid 的预期供应量将增加到 1.2 亿个疗程，意义重大。分析师表示，该公司将销售和分销其中大部分课程，其收入远远超过 SVB Leerink 目前预测的 2022 年 Paxlovid 销售额为 240 亿美元，2023 年为 330 亿美元。</blockquote></p><p> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p><p><blockquote>分析师表示，2024 年收入贡献将降至 100 亿美元。他补充说，预计 2022-24 年 Paxlovid 的总销售额为 670 亿美元，远高于共识。</blockquote></p><p> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p><p><blockquote>Porges说，药物相互作用对Paxlovid摄取的影响将是适度的，因为清单上的许多药物可以在Paxlovid治疗的短时间内暂停，而不会对患者产生重大影响。他补充说，可能被排除在使用 Paxlovid 之外的患者是那些患有严重肝脏或肾脏损害的患者以及那些患有不受控制的 HIV-1 感染的患者。</blockquote></p><p> The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p><p><blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并描绘了与默克公司的molnupiravir相比相对良性的风险/效益概况，后者在动物中显示出胚胎发育和胎儿生长风险。</blockquote></p><p> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p><p><blockquote>Paxlovid 比一些领先的抗体疗法具有更好的疗效，而且由于一些抗体疗法对奥密克戎变异株失去了疗效，Paxlovid 将成为“对医生和患者极具吸引力的选择”，Porges 说。</blockquote></p><p> <b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p><p><blockquote><b>美国银行表示，Paxlovid 应该仍然是一个稳定的贡献者：</b>美国银行分析师米查姆表示，2022 年销售辉瑞生产的每个疗程的 Paxlovid 应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在 2022 年确认每剂疫苗的收入。</blockquote></p><p> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p><p><blockquote>分析师表示，从长远来看，Paxlovid 可能会保持稳定的贡献者。</blockquote></p><p> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p><p><blockquote>“我们预计突破性感染将在地方病阶段继续定期发生，虽然疫苗和既往感染的基线免疫水平将限制严重程度，但我们预计高危个体中发生的新冠病例的治疗将是标准护理，”米查姆说。</blockquote></p><p> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p><p><blockquote>这位分析师表示，预计政府机构将储备默克的药丸，因此可能会进行初步销售。他补充说，从长远来看，Paxlovid 可能是首选药物。</blockquote></p><p> <b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p><p><blockquote><b>辉瑞价格走势：</b>辉瑞股价周四收盘下跌 1.41%，至 58.71 美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698339746,"gmtCreate":1640302554512,"gmtModify":1640302554512,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097106422038760","authorIdStr":"4097106422038760"},"themes":[],"title":"","htmlText":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","listText":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","text":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/698339746","repostId":"1169545714","repostType":4,"repost":{"id":"1169545714","kind":"news","pubTimestamp":1640272530,"share":"https://www.laohunote.com/m/news/1169545714?lang=zh_CN&edition=full","pubTime":"2021-12-23 23:15","market":"us","language":"en","title":"Nio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行提出了有吸引力的购买机会，蔚来受到关注</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169545714","media":"seekingalpha","summary":"Niois a new addition to the fresh money list at Deutsche Bank on what it calls an attractive buying opportunity heading into the new year.Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months w","content":"<p>Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive&nbsp;buying opportunity heading into the new year.</p><p><blockquote>蔚来（纽约证券交易所股票代码：NIO）是德意志银行新基金名单中的新成员，评级了新的一年有吸引力的买入机会。</blockquote></p><p> Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"</p><p><blockquote>分析师 Edison Yu：“由于该股近几个月来表现严重不佳，我们认为这是一个很好的切入点，为关键的 2022 年奠定了基础。由于缺乏新车和供应链限制，以及最近美国退市风险加剧，投资者情绪一直低迷。我们相信，随着蔚来在未来 12 个月内推出 3 款新车型，并将产能从 12 万辆提高到 60 万辆，这些不利因素都可以在未来 12 个月内全部逆转。”</blockquote></p><p> Yu points to a big year for the ET5 model in particular.</p><p><blockquote>Yu 指出，ET5 车型今年尤其重要。</blockquote></p><p> Deutsche Bank keeps a Buy rating on the Chinese EV stock.</p><p><blockquote>德意志银行维持中国电动汽车股票的买入评级。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行提出了有吸引力的购买机会，蔚来受到关注</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行提出了有吸引力的购买机会，蔚来受到关注</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-12-23 23:15</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive&nbsp;buying opportunity heading into the new year.</p><p><blockquote>蔚来（纽约证券交易所股票代码：NIO）是德意志银行新基金名单中的新成员，评级了新的一年有吸引力的买入机会。</blockquote></p><p> Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"</p><p><blockquote>分析师 Edison Yu：“由于该股近几个月来表现严重不佳，我们认为这是一个很好的切入点，为关键的 2022 年奠定了基础。由于缺乏新车和供应链限制，以及最近美国退市风险加剧，投资者情绪一直低迷。我们相信，随着蔚来在未来 12 个月内推出 3 款新车型，并将产能从 12 万辆提高到 60 万辆，这些不利因素都可以在未来 12 个月内全部逆转。”</blockquote></p><p> Yu points to a big year for the ET5 model in particular.</p><p><blockquote>Yu 指出，ET5 车型今年尤其重要。</blockquote></p><p> Deutsche Bank keeps a Buy rating on the Chinese EV stock.</p><p><blockquote>德意志银行维持中国电动汽车股票的买入评级。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3783031-nio-is-on-watch-with-attractive-buying-opportunity-called-out-by-deutsche-bank\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/news/3783031-nio-is-on-watch-with-attractive-buying-opportunity-called-out-by-deutsche-bank","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169545714","content_text":"Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive buying opportunity heading into the new year.\nAnalyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"\nYu points to a big year for the ET5 model in particular.\nDeutsche Bank keeps a Buy rating on the Chinese EV stock.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":4885,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":698339746,"gmtCreate":1640302554512,"gmtModify":1640302554512,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097106422038760","authorIdStr":"4097106422038760"},"themes":[],"title":"","htmlText":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","listText":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","text":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/698339746","repostId":"1169545714","repostType":4,"repost":{"id":"1169545714","kind":"news","pubTimestamp":1640272530,"share":"https://www.laohunote.com/m/news/1169545714?lang=zh_CN&edition=full","pubTime":"2021-12-23 23:15","market":"us","language":"en","title":"Nio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行提出了有吸引力的购买机会，蔚来受到关注</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169545714","media":"seekingalpha","summary":"Niois a new addition to the fresh money list at Deutsche Bank on what it calls an attractive buying opportunity heading into the new year.Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months w","content":"<p>Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive&nbsp;buying opportunity heading into the new year.</p><p><blockquote>蔚来（纽约证券交易所股票代码：NIO）是德意志银行新基金名单中的新成员，评级了新的一年有吸引力的买入机会。</blockquote></p><p> Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"</p><p><blockquote>分析师 Edison Yu：“由于该股近几个月来表现严重不佳，我们认为这是一个很好的切入点，为关键的 2022 年奠定了基础。由于缺乏新车和供应链限制，以及最近美国退市风险加剧，投资者情绪一直低迷。我们相信，随着蔚来在未来 12 个月内推出 3 款新车型，并将产能从 12 万辆提高到 60 万辆，这些不利因素都可以在未来 12 个月内全部逆转。”</blockquote></p><p> Yu points to a big year for the ET5 model in particular.</p><p><blockquote>Yu 指出，ET5 车型今年尤其重要。</blockquote></p><p> Deutsche Bank keeps a Buy rating on the Chinese EV stock.</p><p><blockquote>德意志银行维持中国电动汽车股票的买入评级。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行提出了有吸引力的购买机会，蔚来受到关注</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行提出了有吸引力的购买机会，蔚来受到关注</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-12-23 23:15</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive&nbsp;buying opportunity heading into the new year.</p><p><blockquote>蔚来（纽约证券交易所股票代码：NIO）是德意志银行新基金名单中的新成员，评级了新的一年有吸引力的买入机会。</blockquote></p><p> Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"</p><p><blockquote>分析师 Edison Yu：“由于该股近几个月来表现严重不佳，我们认为这是一个很好的切入点，为关键的 2022 年奠定了基础。由于缺乏新车和供应链限制，以及最近美国退市风险加剧，投资者情绪一直低迷。我们相信，随着蔚来在未来 12 个月内推出 3 款新车型，并将产能从 12 万辆提高到 60 万辆，这些不利因素都可以在未来 12 个月内全部逆转。”</blockquote></p><p> Yu points to a big year for the ET5 model in particular.</p><p><blockquote>Yu 指出，ET5 车型今年尤其重要。</blockquote></p><p> Deutsche Bank keeps a Buy rating on the Chinese EV stock.</p><p><blockquote>德意志银行维持中国电动汽车股票的买入评级。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3783031-nio-is-on-watch-with-attractive-buying-opportunity-called-out-by-deutsche-bank\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/news/3783031-nio-is-on-watch-with-attractive-buying-opportunity-called-out-by-deutsche-bank","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169545714","content_text":"Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive buying opportunity heading into the new year.\nAnalyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"\nYu points to a big year for the ET5 model in particular.\nDeutsche Bank keeps a Buy rating on the Chinese EV stock.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":4885,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698332753,"gmtCreate":1640303160546,"gmtModify":1640303160546,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097106422038760","authorIdStr":"4097106422038760"},"themes":[],"title":"","htmlText":"Merry Christmas 🥂","listText":"Merry Christmas 🥂","text":"Merry Christmas 🥂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698332753","repostId":"2193078140","repostType":2,"isVote":1,"tweetType":1,"viewCount":3242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696418210,"gmtCreate":1640745892996,"gmtModify":1640745892996,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097106422038760","authorIdStr":"4097106422038760"},"themes":[],"title":"","htmlText":"Thanks for sharing! 👍🏻","listText":"Thanks for sharing! 👍🏻","text":"Thanks for sharing! 👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696418210","repostId":"1143687105","repostType":4,"repost":{"id":"1143687105","kind":"news","pubTimestamp":1640743835,"share":"https://www.laohunote.com/m/news/1143687105?lang=zh_CN&edition=full","pubTime":"2021-12-29 10:10","market":"us","language":"en","title":"APPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>APPS 股票提醒：有关 Google 交易的 7 件事，您需要了解今天提振 Digital Turbine 股价</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143687105","media":"InvestorPlace","summary":"Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed ","content":"<p><div> Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google...</p><p><blockquote><div>Digital Turbine（纳斯达克股票代码：APPS）的股价今天下滑，尽管这家科技公司宣布已同意与Alphabet（纳斯达克股票代码：GOOG，纳斯达克股票代码：GOOGL）的谷歌公司建立 “多年战略合作伙伴关系”。</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>APPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>APPS 股票提醒：有关 Google 交易的 7 件事，您需要了解今天提振 Digital Turbine 股价</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAPPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>APPS 股票提醒：有关 Google 交易的 7 件事，您需要了解今天提振 Digital Turbine 股价</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-29 10:10</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google...</p><p><blockquote><div>Digital Turbine（纳斯达克股票代码：APPS）的股价今天下滑，尽管这家科技公司宣布已同意与Alphabet（纳斯达克股票代码：GOOG，纳斯达克股票代码：GOOGL）的谷歌公司建立 “多年战略合作伙伴关系”。</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOOG":"谷歌","APPS":"Digital Turbine Inc."},"source_url":"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143687105","content_text":"Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google. Digital Turbine’s technology enhances mobile ads and the monetization of mobile traffic. In early trading, APPS stock is down 1.73% to $62.34 amid much higher than normal volume.\nDigital Turbine did not disclose the financial terms of the alliance. However, here are seven things that we do know about the deal.\n\nDigital Turbine is going to collaborate with Google Cloud’s partner,SADA.\nDigital Turbine and SADA will attempt to quickly improve and geographically expand Google Cloud’s “enterprise and cloud solutions.”\nThe two companies will also seek to develop additional “growth and monetization” opportunities for Google’s “partners.”\nDigital Turbine will use Google’s “advanced cloud and enterprise infrastructure.”\nThe company will, for the first time, enhance the “mobile experiences” of overseas Android users.\nMore specifically, Digital Turbine will enable “app discovery for nearly a billion Android devices globally.”\nDigital Turbine will be supporting “mobile, TV and connected devices” that utilize Android.\n\nOther Things to Know About APPS Stock\nIn the last month, APPS stock has rallied over 20%. However, shares are still down nearly 30% from their late October peak. The stock now has a market capitalization of nearly $6.4 billion and is trading at a hefty, but not huge, trailing price-to-sales ratio of 7.45.\nAdditionally, institutional investors hold 75% of the shares. Among the largest institutional owners of the stock, as of Sept. 29, were Blackrock(NYSE:BLK) with a 10% stake,Wellington Management Group with a 6.55% stake,Vanguard Group with a 9.17% stake,State Street(NYSE:STT) with a 2.86% stake, and JPMorgan(NYSE:JPM), which owned 1.86% of the company.","news_type":1,"symbols_score_info":{"GOOG":0.9,"APPS":0.9}},"isVote":1,"tweetType":1,"viewCount":3591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698333856,"gmtCreate":1640302633989,"gmtModify":1640302633989,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097106422038760","authorIdStr":"4097106422038760"},"themes":[],"title":"","htmlText":"Watching this space closely 😬","listText":"Watching this space closely 😬","text":"Watching this space closely 😬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698333856","repostId":"1172289344","repostType":4,"repost":{"id":"1172289344","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohunote.com/m/news/1172289344?lang=zh_CN&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服 COVID-19 药丸能带来多少收入？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga Earnings","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p><p><blockquote><b>辉瑞公司。</b>周三宣布其口服 COVID-19 抗病毒药物，<b>帕克斯洛维德，</b>已被美国授权使用。食品药品监督管理局。</blockquote></p><p> <b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p><p><blockquote><b>辉瑞分析师：</b>SVB Leerink 分析师 Geoffrey Porges 对辉瑞给予市场表现评级，目标价为 52 美元。</blockquote></p><p> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p><p><blockquote>美国银行证券分析师杰夫·米查姆维持中性评级，目标价为 59 美元。</blockquote></p><p> <b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p><p><blockquote><b>广泛的标签，增加供应，使辉瑞占据市场主导地位：</b>辉瑞提前获得口服 COVID-19 治疗的批准<b>默克公司。</b>波吉斯在一份报告中表示，该公司比辉瑞早一个多月提交了莫努匹拉韦的申请。</blockquote></p><p> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p><p><blockquote>该分析师认为辉瑞明年 Paxlovid 的预期供应量将增加到 1.2 亿个疗程，意义重大。分析师表示，该公司将销售和分销其中大部分课程，其收入远远超过 SVB Leerink 目前预测的 2022 年 Paxlovid 销售额为 240 亿美元，2023 年为 330 亿美元。</blockquote></p><p> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p><p><blockquote>分析师表示，2024 年收入贡献将降至 100 亿美元。他补充说，预计 2022-24 年 Paxlovid 的总销售额为 670 亿美元，远高于共识。</blockquote></p><p> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p><p><blockquote>Porges说，药物相互作用对Paxlovid摄取的影响将是适度的，因为清单上的许多药物可以在Paxlovid治疗的短时间内暂停，而不会对患者产生重大影响。他补充说，可能被排除在使用 Paxlovid 之外的患者是那些患有严重肝脏或肾脏损害的患者以及那些患有不受控制的 HIV-1 感染的患者。</blockquote></p><p> The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p><p><blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并描绘了与默克公司的molnupiravir相比相对良性的风险/效益概况，后者在动物中显示出胚胎发育和胎儿生长风险。</blockquote></p><p> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p><p><blockquote>Paxlovid 比一些领先的抗体疗法具有更好的疗效，而且由于一些抗体疗法对奥密克戎变异株失去了疗效，Paxlovid 将成为“对医生和患者极具吸引力的选择”，Porges 说。</blockquote></p><p> <b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p><p><blockquote><b>美国银行表示，Paxlovid 应该仍然是一个稳定的贡献者：</b>美国银行分析师米查姆表示，2022 年销售辉瑞生产的每个疗程的 Paxlovid 应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在 2022 年确认每剂疫苗的收入。</blockquote></p><p> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p><p><blockquote>分析师表示，从长远来看，Paxlovid 可能会保持稳定的贡献者。</blockquote></p><p> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p><p><blockquote>“我们预计突破性感染将在地方病阶段继续定期发生，虽然疫苗和既往感染的基线免疫水平将限制严重程度，但我们预计高危个体中发生的新冠病例的治疗将是标准护理，”米查姆说。</blockquote></p><p> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p><p><blockquote>这位分析师表示，预计政府机构将储备默克的药丸，因此可能会进行初步销售。他补充说，从长远来看，Paxlovid 可能是首选药物。</blockquote></p><p> <b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p><p><blockquote><b>辉瑞价格走势：</b>辉瑞股价周四收盘下跌 1.41%，至 58.71 美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服 COVID-19 药丸能带来多少收入？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服 COVID-19 药丸能带来多少收入？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-12-24 07:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p><p><blockquote><b>辉瑞公司。</b>周三宣布其口服 COVID-19 抗病毒药物，<b>帕克斯洛维德，</b>已被美国授权使用。食品药品监督管理局。</blockquote></p><p> <b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p><p><blockquote><b>辉瑞分析师：</b>SVB Leerink 分析师 Geoffrey Porges 对辉瑞给予市场表现评级，目标价为 52 美元。</blockquote></p><p> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p><p><blockquote>美国银行证券分析师杰夫·米查姆维持中性评级，目标价为 59 美元。</blockquote></p><p> <b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p><p><blockquote><b>广泛的标签，增加供应，使辉瑞占据市场主导地位：</b>辉瑞提前获得口服 COVID-19 治疗的批准<b>默克公司。</b>波吉斯在一份报告中表示，该公司比辉瑞早一个多月提交了莫努匹拉韦的申请。</blockquote></p><p> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p><p><blockquote>该分析师认为辉瑞明年 Paxlovid 的预期供应量将增加到 1.2 亿个疗程，意义重大。分析师表示，该公司将销售和分销其中大部分课程，其收入远远超过 SVB Leerink 目前预测的 2022 年 Paxlovid 销售额为 240 亿美元，2023 年为 330 亿美元。</blockquote></p><p> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p><p><blockquote>分析师表示，2024 年收入贡献将降至 100 亿美元。他补充说，预计 2022-24 年 Paxlovid 的总销售额为 670 亿美元，远高于共识。</blockquote></p><p> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p><p><blockquote>Porges说，药物相互作用对Paxlovid摄取的影响将是适度的，因为清单上的许多药物可以在Paxlovid治疗的短时间内暂停，而不会对患者产生重大影响。他补充说，可能被排除在使用 Paxlovid 之外的患者是那些患有严重肝脏或肾脏损害的患者以及那些患有不受控制的 HIV-1 感染的患者。</blockquote></p><p> The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p><p><blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并描绘了与默克公司的molnupiravir相比相对良性的风险/效益概况，后者在动物中显示出胚胎发育和胎儿生长风险。</blockquote></p><p> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p><p><blockquote>Paxlovid 比一些领先的抗体疗法具有更好的疗效，而且由于一些抗体疗法对奥密克戎变异株失去了疗效，Paxlovid 将成为“对医生和患者极具吸引力的选择”，Porges 说。</blockquote></p><p> <b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p><p><blockquote><b>美国银行表示，Paxlovid 应该仍然是一个稳定的贡献者：</b>美国银行分析师米查姆表示，2022 年销售辉瑞生产的每个疗程的 Paxlovid 应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在 2022 年确认每剂疫苗的收入。</blockquote></p><p> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p><p><blockquote>分析师表示，从长远来看，Paxlovid 可能会保持稳定的贡献者。</blockquote></p><p> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p><p><blockquote>“我们预计突破性感染将在地方病阶段继续定期发生，虽然疫苗和既往感染的基线免疫水平将限制严重程度，但我们预计高危个体中发生的新冠病例的治疗将是标准护理，”米查姆说。</blockquote></p><p> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p><p><blockquote>这位分析师表示，预计政府机构将储备默克的药丸，因此可能会进行初步销售。他补充说，从长远来看，Paxlovid 可能是首选药物。</blockquote></p><p> <b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p><p><blockquote><b>辉瑞价格走势：</b>辉瑞股价周四收盘下跌 1.41%，至 58.71 美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}